This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.
CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.
Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance
by Zacks Equity Research
Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down
by Zacks Equity Research
Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.
Align Technology (ALGN) Q2 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Align Technology (ALGN) delivers impressive earnings in the second quarter of 2023.
Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.
Universal Health (UHS) Q2 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
Universal Health's (UHS) Q2 results indicate improved patient admissions and solid segmental performance. Management currently expects adjusted EPS within $9.85-$10.50 for 2023.
Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Challenging macroeconomic conditions and slowdown in activities in China impede Thermo Fisher's (TMO) Q2 revenues.
Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART
by Urmimala Biswas
Medical Device companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, LH and IART fare this time.
Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) first-quarter fiscal 2024 results reflect strength in its revenue sources.
Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acadia Pharmaceuticals (ACAD) and Abbott (ABT) have performed compared to their sector so far this year.
Company News for Jul 21, 2023
by Zacks Equity Research
Companies In The News Are: KMI, UAL, ABT, IBM.
Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023
Abbott (ABT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.85% and 2.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Big Cap Earnings Charts to Watch This Week
by Tracey Ryniec
We are going to get a good look at the global economy.
2 Medical Stocks to Buy as Earnings Approach
by Shaun Pruitt
Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week's earnings lineup.
Here's Why You Should Add BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Why Abbott (ABT) Might Surprise This Earnings Season
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.